The London Life Sciences team advised Huma Therapeutics on the completion of its latest funding round with financing of approximately $130 million. The round was led by Leaps by Bayer and Hitachi Ventures, and included participation from new investors such as HAT Group, Nomura Bank, Samsung, Sony and Unilever. The investment will allow scale Huma’s modular platform which can power digital ‘hospitals at home’ nationally, and support the pharmaceutical and research industries to run the largest ever decentralized clinical trials. Huma's platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.
Huma is a global health tech company and its software solutions support healthcare organisations by providing greater access to care remotely and empowers patients to better manage their own health. Huma’s solutions also support the remote collection of patient generated data through remote patient monitoring, real-world monitoring and the development of digital biomarkers and companion products with partners.